Colitis After SARS-CoV-2 Infection

Gill, Rajwinder; Siau, Evan

doi:10.7759/cureus.26532

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We could reasonably anticipate that the data carry prominent clinical implications for curbing severe COVID-19 illnesses arising from the current sublineages of the Omicron variant and are likely to resonate with growing evidence from future large-scale randomized controlled trials and real-world studies to recommend the use of bebtelovimab in a broader range of patients. Whilst bebtelovimab appears to be well tolerated in our review, case reports have documented that a patient experienced sinus bradycardia-mediated cardiac arrest immediately following infusion of bebtelovimab (63) and another patient developed colitis 10 days after the use of bebtelovimab (64). Postmarketing surveillance for adverse events and ad hoc safety studies are henceforth crucial for earlier detection of safety issues and preventing patients from unnecessary harm (65).…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis

Liew,

Kua,

Lee

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThe COVID-19 pandemic is a major global public health crisis. More than 2 years into the pandemic, effective therapeutic options remain limited due to rapid viral evolution. Stemming from the emergence of multiple variants, several monoclonal antibodies are no longer suitable for clinical use. This scoping review aimed to summarize the preclinical and clinical evidence for bebtelovimab in treating newly emerging SARS-CoV-2 variants.MethodsWe systematically searched five electronic databases (PubMed, CENTRAL, Embase, Global Health, and PsycINFO) from date of inception to September 30, 2022, for studies reporting on the effect of bebtelovimab in SARS-CoV-2 infection, using a combination of search terms around ―bebtelovimab‖, ―LY-CoV1404‖, ―LY3853113‖, and ―coronavirus infection‖. All citations were screened independently by two researchers. Data were extracted and thematically analyzed based on study design by adhering to the stipulated scoping review approaches.ResultsThirty-nine studies were included, thirty-four non-clinical studies were narratively synthesized, and five clinical studies were meta-analyzed. The non-clinical studies revealed bebtelovimab not only potently neutralized wide-type SARS-CoV-2 and existing variants of concern such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta), but also retained appreciable activity against Omicron lineages, including BA.2.75, BA.4, BA.4.6, and BA.5. Unlike other monoclonal antibodies, bebtelovimab was able to bind to epitope of the SARS-CoV-2 S protein by exploiting loop mobility or by minimizing side-chain interactions. Pooled analysis from clinical studies depicted that the rates of hospitalization, ICU admission, and death were similar between bebtelovimab and other COVID-19 therapies. Bebtelovimab was associated with a low incidence of treatment-emergent adverse events.ConclusionPreclinical evidence suggests bebtelovimab be a potential treatment for COVID-19 amidst viral evolution. Bebtelovimab has comparable efficacy to other COVID-19 therapies without evident safety concerns.

show abstract

Section: Discussionmentioning

confidence: 99%